Patient-reported side effects comparing Mitomycin administered at weekly sessions and within 24 hours after TURB - A Comparative study

Introduction and Objectives

Mitomycin (MC) is a cytostaticum used locally in the bladder after transurethral resection of the bladder (TURB) in patients diagnosed with non-invasive bladder cancer (NMIBC). MC is first line treatment in NMIBC and is usually given as a single treatment after TURB or once a week during a period of eight weeks. Most common side effects are irritative voiding symptoms and skin irritation by direct genital contact as well as by rash of hands and feet.

The aim of the study was to compare patient-reported side effects between weekly MC instilment and MC instilment within 24 hours after TURB to improve knowledge and optimize clinical decision-making.

Material and Methods


A retrospective study based on a survey among 65 patients undergoing TURB at Randers Regional Hospital, Denmark who had MC instilled in the bladder within 24 hours. The day after instillation of MC, the patient was followed-up by telephone and side effects were documented using a standardized questionnaire.

In 2016, 11 patients at Aarhus University Hospital started instillation of MC over a period of eight weeks in an outpatient setting. At every consultation we discussed urination, side effects and whether the patient had been able to contain the MC for the prescribed 2 hours since the last consultation.

The medical files of each patient were examined to compare documented side effects.

Discussion

Overall 8 weekly treatments seems to have more serious side effect especially voiding symptoms compared with a single treatment according to patient reported events. A total of 8 visits to the Hospital may influence at the quality of life for the patient although not significantly documented and solely based on subjective estimation.



Results

Table 1

Comparison of sideeffects between two types of MC installatiotherapy reported by proportions

Most common side effects	MC instilled 24 hours after TURB*	%	MC instilled once a week** (8 weeks)	%
Skin irritation	3	4,б	3	21
Urgency	30	46	7	50
Infection	0	0	4	29
<i>Ability to contain Mitomycin in the bladder for 2 hours</i>	33	51	6	43

*65 patients: 20 women and 45 men, **11 patients: 6 women and 5 men

Skin irritation was more frequent in patients treated weekly during eight weeks in the outpatient clinic. Urgency was seen in around 50% of patients in both groups; infection was only observed in patients receiving weekly treatments. The ability to contain MC was higher among patients who had the treatment within 24 hours compared to weekly installations. The overall experience was that the number of side effects increased and correlated with time of treatment.

Table 2


MC instilled in the bladder within 24 hours? after TURB as a single treatment

1	••		
	Advantages	N.	Disadvantages
	MC instilled through the already inserted catheter		The patient have to wait the bladder is acceptable
	No additional transportation to the hospital		Free voiding have to be i
	Socioeconomic advantage due to a single treatment		Hard to contain MC in th prescribed 2 hours
			Extra staff resources in th

Extra staff resources in the inpatient department

Table 3

MC given in an outpatient setting once a week for 8 weeks



t until the bleeding from insured the bladder during the

Side effects may be experienced for a longer period Costs of 8 treatments with MC is expensive due to

Perspective

The results vidness that we might re-visit the patient-pathways and concider the following questions: • Is it necessary to make changes in care-pathways using MC?

- treatment?
- home?

Conclusion

This study suggests, although based on limited data, that patients who only received treatment within 24 hours after TURB had less self-reported side-effects compared to those treated weekly for eight weeks in the outpatient clinic. However, it would require further research and more data to qualify a comparison between treatment modalities and thereby evidence for a permanent change of the patient-pathway.



HJULER, A RN Continence Adviser, Department of Urology, Aarhus University Hospital, Denmark annehjul@rm.dk

Nr 48

• Is it possible that the patient could influence the choice of

• Is it possible to involve the primary care nurse so the patient can have treatments with MC in a nurse-led clinic or at



